Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL971221 | 1.00 | REN (0.64) | RENCYP3A4 | |
| SCHEMBL971860 | 0.92 | REN (0.65) | RENCYP3A4 | |
| SCHEMBL972061 | 0.89 | REN (0.62) | RENCYP3A4 | |
| SCHEMBL972062 | 0.89 | REN (0.62) | RENCYP3A4 | |
| SCHEMBL4294985 | 0.88 | REN (0.64) | RENCYP3A4 | |
| SCHEMBL4299952 | 0.88 | REN (0.64) | RENCYP3A4 | |
| SCHEMBL4294990 | 0.88 | REN (0.64) | RENCYP3A4 | |
| SCHEMBL4299992 | 0.86 | REN (0.85) | RENCYP3A4 | |
| SCHEMBL4299993 | 0.86 | REN (0.85) | RENCYP3A4 | |
| SCHEMBL4299276 | 0.86 | REN (0.85) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872028-B2 | Diaminopropanol renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | VITAE PHARMACEUTICALS, INC. | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | DNPEP, ACE, DPEP1 | REN 13/4885CYP3A4 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.